top of page

Screening for Diabetic Retinopathy Using AI Instead of Referring to a Specialist
AEYE Health’s FDA-cleared AI delivers fast, autonomous diabetic retinopathy screening directly in your endocrinology clinic. In just 1 minute, staff can complete screening during routine visits, streamlining the care pathway and reducing the risk of diabetes-related vision loss. In-office screening also generates reimbursement through CPT 92229 while helping improve diabetic eye exam adherence and HEDIS performance.
Advantages of AEYE-DS

Seamless EMR Integration
Full integration with Epic and other EMR systems, enabling automated coding, billing, reporting and referral
_edited.png)
1-minute Screening
Requires only one image per eye; no dilation; producing instant diagnosis

Practical to Operate
Can be operated with a portable handheld camera and a robotic tabletop camera
Benefits of Point of Care Screening
_edited.png)
Reimbursable​
Dedicated CPT code 92229 for AI diabetic retinopathy screening

Closes Care Gaps​
Closes the care diabetic eye gap, improving HEDIS scores and Star ratings

Improve Patient Outcomes
Point-of-care screening ensures adherence to screening protocols and protects patients’ sight
Billing and Reimbursement for Diabetic Retinopathy Screening in Primary Care

Reimbursable by Endocrinologists
CPT code 92229 was created for endocrinology providers and covers retinal imaging for the detection or monitoring of diabetic retinopathy, including point-of-care automated analysis and reporting.
Improves HEDIS scores and Star-ratings
Diabetic eye exams performed by endocrinology providers can be reported using CPT Category II codes and counted toward various HEDIS measures, helping practices enhance quality metrics and patient outcomes.
Addresses point-of-care screening payment programs
Screening for diabetic retinopathy addresses MIPS measure 117 and may qualify PCPs for additional payer incentives

Explore How You Can Implement Sight-Saving Diagnostic Screening
Schedule a Demo
bottom of page
